Literature DB >> 3594455

Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition.

G Spignoli, F Pedata, L Giovannelli, S Banfi, F Moroni, G Pepeu.   

Abstract

Oxiracetam at 100 and 300 mg/kg i.p. dose levels increased acetylcholine (ACh) utilization in the rat cerebral cortex and hippocampus. ACh utilization was assessed by measuring, with a gas chromatographic method, the decrease in ACh level after inhibiting its synthesis by 15 micrograms intracerebroventricularly (i.c.v.) injection of hemicholinium (HC-3). ACh steady state levels were not affected. Piracetam (300 mg/kg i.p.) also increased ACh utilization in the hippocampus. Repeated daily administration of oxiracetam 100 mg/kg i.p. caused a 31% increase in high-affinity choline uptake (HACU) in the hippocampus. A single administration of 300 mg/kg i.p. of oxiracetam and piracetam also increased HACU rate in the hippocampus. However, the effect of piracetam was over within 3 h, while 3 h after its administration oxiracetam still caused a 40% increase in HACU rate. Oxiracetam (100 mg/kg i.p.) significantly antagonized the impairment in the acquisition of an active-avoidance conditioned response (pole climbing) associated with the inhibition of ACh synthesis by HC-3. These results indicate that oxiracetam enhances the activity of the septohippocampal cholinergic pathways, and to a lesser extent, of the cortical cholinergic network.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3594455

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

1.  Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat.

Authors:  V Santucci; M Fournier; P Worms; P Keane; K Bizière
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

2.  Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type.

Authors:  L Parnetti; P Mecocci; A Gaiti; D Cadini; F Lombardi; M Visconti; U Senin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

3.  Modulating effect of the nootropic drug, piracetam on stress- and subsequent morphine-induced prolactin secretion in male rats.

Authors:  A Matton; S Engelborghs; F Bollengier; E Finné; L Vanhaeist
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties.

Authors:  J A Miller; M W Dudley; J H Kehne; S M Sorensen; J M Kane
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

5.  Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis.

Authors:  M G Giovannini; F Casamenti; A Nistri; F Paoli; G Pepeu
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

6.  Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain.

Authors:  E Abe
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 7.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.